Accession Number:



Quantitative PET Imaging with Novel HER3-Targeted Peptides Selected by Phage Display to Predict Androgen-Independent Prostate Cancer Progression

Descriptive Note:

[Technical Report, Final Report]

Corporate Author:

Massachusetts General Hospital

Personal Author(s):

Report Date:


Pagination or Media Count:



Funding from this award has permitted the development of a highly specific peptide that targets HER3 for prostate cancer imaging. The peptide was labeled with a PET imaging radionuclide and injected into mice bearing human prostate cancer. The peptide accumulated at high levels in the tumors, and excisional analysis revealed quantitative accumulation of the peptide in tumors that was linearly correlated with HER3 levels. Biodistribution analysis revealed low off-target accumulation and rapid clearance through the renal system, consistent with small peptides. The peptide represents a promising clinical lead for HER3 imaging in patients with castration resistant prostate cancer.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]